This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Starmer carries out another cabinet reshuffle in the wake of Rayner's resignation, appointing David Lammy as Deputy Prime Minister, Yvette Cooper as Foreign Secretary, and Shabana Mahmood as Home Secretary. Douglas Alexander is appointed Secretary of State for Scotland, replacing Ian Murray. Nigel Farage makes his keynote speech to the Reform UK annual conference, telling delegates they must prepare for an early election following Rayner's resignation. Members of the public are temporarily banned from the chamber of the House of Commons after a mobile phone was found hidden there during a security search. 8 September – The UK government outlines a new defence industrial strategy with £250m of investment in five local economies with a view to creating jobs and fuel growth. Kevin Stewart, a former Scottish Government minister and the MSP for Aberdeen Central, announces he will stand down from Holyrood at the 2026 election on health grounds. 9 September – A message from Peter Mandelson, the UK's ambassador to the United States, is included in a "birthday book" of messages to convicted paedophile Jeffrey Epstein released by the US Congress. Bridget Phillipson, Lucy Powell and Bell Ribeiro-Addy are the three Labour MPs with the most nominations for the Labour Party deputy leadership contest; they must reach 80 nominations to enter the contest. First Minister of Scotland John Swinney meets US President Donald Trump at the White House, where they have what are described as "constructive discussions" about tariffs on the import of scotch whisky to the United States.
Imogen Heap – vocals, production, mixing, engineering, programming Ashwin Srinivasan – background vocals (track 6), flute (track 6) Leo Abrahams – electric guitar (tracks 2, 6) David Daniels—electric guitar (track 6) Oli Langford – violin (tracks 2, 6, 9–10, 12–13) Ian Burdge – cello (tracks 6, 8, 10, 12–13) Richie Mills – drums (tracks 6, 9) Arve Henriksen – trumpet (tracks 8, 13) Simon Heyworth – mastering
==== Unanimous selection for Most Valuable Player Award (1994) ==== The most productive season in Bagwell's professional career was the strike-shortened 1994 season which set several franchise records. On Opening Day, April 4, against the Montreal Expos, Bagwell hit the game-tying home run while going 3-for-6 as the Astros won in a 12-inning walk-off. For the month of April, he batted .360 with six home runs and added another six home runs in May. In June, he hit 13 home runs, establishing an Astros' franchise record for one month, while batting .394, 11 doubles, .455 OBP, .899 SLG, and 1.354 OPS. On June 24, in a 16–4 rout of the Los Angeles Dodgers at the Astrodome, he hit three home runs, including two in the same inning, becoming the first Astro since Glenn Davis in 1990 to do so. Bagwell was the NL Player of the Week for consecutive weeks on June 19 and June 26 and the NL Player of the Month for June, his second career monthly award. Selected to his first All-Star Game as a reserve, Bagwell had tied Kirby Puckett for the major league RBI lead at 81 going into the All-Star break, and batted .348 with 27 home runs and 74 runs scored. In the All-Star Game, Bagwell entered as a pinch hitter for starting pitcher Greg Maddux, singling off David Cone, and wound up collecting two hits in four at bats. The first player in the majors to reach 100 RBI on July 27, Bagwell homered off José Rijo in a 6–5 win over Cincinnati to give him 101 RBI in his first 101 games. In July, he tied a club record for RBI in any month with 29, which José Cruz and Jimmy Wynn shared.
== Early life and education == Following high school graduation, DeGrado worked in a coat rack factory, an experience that motivated him to further his education. He attended colleges in the Chicago suburbs, while running a lawn-mowing service. DeGrado received his B.A. in chemistry from Kalamazoo College (1978) and a doctorate in organic chemistry from the University of Chicago (1981).
Sources: en.wikipedia.org
Hindu-Arabic numerals were not originally designed to indicate their numeric value through the number of angles they contain. There are no historical records of this, and the myth is difficult to reconcile with digits past 3 or 4. The Greek philosopher Pythagoras was not the first to discover what is now called the Pythagorean theorem, as it was known and used by the Babylonians and Indians centuries before him. Pythagoras may have been the first to introduce it to the Greeks, but the first record of it being mathematically proven as a theorem is in Euclid's Elements which was published some 200 years after Pythagoras. There is no evidence that the ancient Greeks deliberately designed the Parthenon to match the golden ratio. The Parthenon was completed in 438 BCE, more than a century before the first recorded mention of the ratio by Euclid. Similarly, Leonardo da Vinci's Vitruvian Man makes no mention of the golden ratio in its text, although it describes many other proportions. The repeating decimal written as 0.999... represents exactly the same quantity as 1. The p-value is not the probability that the null hypothesis is true, or the probability that the alternative hypothesis is false; it is the probability of obtaining results at least as extreme as the results actually observed under the assumption that the null hypothesis was correct, which can indicate the incompatibility of results with the specific statistical model assumed in the null hypothesis. This misconception, and similar ones like it, contributes to the common misuse of p-values in education and research.
Both normal "red" marrow and pathologic marrow lesions (such as cancer) are darker than "yellow" marrow on T1-weight sequences, although can often be distinguished by comparison with the MR signal intensity of adjacent soft tissues. Normal "red" marrow is typically equivalent or brighter than skeletal muscle or intervertebral disc on T1-weighted sequences. Fatty marrow change, the inverse of red marrow hyperplasia, can occur with normal aging, though it can also be seen with certain treatments such as radiation therapy. Diffuse marrow T1 hypointensity without contrast enhancement or cortical discontinuity suggests red marrow conversion or myelofibrosis. Falsely normal marrow on T1 can be seen with diffuse multiple myeloma or leukemic infiltration when the water to fat ratio is not sufficiently altered, as may be seen with lower grade tumors or earlier in the disease process.
== Structure == MOFs are composed of two main components: an inorganic metal cluster (often referred to as a secondary-building unit or SBU) and an organic molecule called a linker. For this reason, the materials are often referred to as hybrid organic-inorganic materials. The organic units are typically mono-, di-, tri-, or tetravalent ligands. The choice of metal and linker dictates the structure and hence properties of the MOF. For example, the metal's coordination preference influences the size and shape of pores by dictating how many ligands can bind to the metal, and in which orientation.
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.